Sandra A. S. Johnson
Associate Dean
Also affiliated: University of Southern California (2000–2014); Michigan Department of Health and Human Services (2016); The Royal Melbourne Hospital (2010–2020); Queensland University of Technology (2022); The University of Melbourne (2004–2025); Baylor College of Medicine (2017); Walter and Eliza Hall Institute of Medical Research (2010); University of North Dakota (2000); Peter MacCallum Cancer Centre (2005–2010); St Vincent's Hospital Melbourne (2003–2004); Department of Health and Human Services (2019); Peter Doherty Institute (2016–2022); Health Protection Agency (2013); Victorian Aboriginal Health Service (2016–2020); USC Norris Comprehensive Cancer Center (2008); Cancer Genetics (United States) (2006); St Mary's Hospital (1990); Ian Potter Foundation (2005); Duchess Of Kent Hospital (2015); MilliporeSigma (United States) (2024–2025); University of Missouri (2023)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Sandra A. S. Johnson's research has explored various aspects of molecular biology and disease mechanisms. She has investigated the role of gene expression regulation in oncogenic transformation, specifically examining how enhanced RNA Polymerase III-dependent transcription contributes to cellular transformation. Her work also delves into the molecular underpinnings of bone-related conditions, including studies on terminal osteoblast differentiation and its disruption in osteosarcoma, as well as the molecular profiling of giant cell tumor of bone and the osteoclastic localization of key signaling molecules. Additionally, Johnson has contributed to research on microbial infections, focusing on molecular and imaging techniques for bacterial biofilms in joint arthroplasty infections and the comparative efficacy of antibiotics in treating *Staphylococcus aureus* bacteremia. Her publications also extend to public health and clinical studies, including research on antiretroviral preexposure prophylaxis for HIV transmission and comparative analyses of treatments for plaque psoriasis and MRSA bacteremia.
Metrics
- h-index: 21
- Publications: 69
- Citations: 3,919
Positions
-
Associate DeanUniversity of Denver Josef Korbel School of International Studies ORCID
-
Associate Dean publications 2025University of Arkansas – Fort Smith ORCID
Selected Publications
-
Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium (2026)
-
Genital Psoriasis: Shining Light on This Hidden Disease (2025)
-
Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial (2023)
Collaboration Network
Top Collaborators
- Genital Psoriasis: Shining Light on This Hidden Disease
- Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium
- Genital Psoriasis: Shining Light on This Hidden Disease
- Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium
- Genital Psoriasis: Shining Light on This Hidden Disease
- Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium
- The role of brimonidine tartrate gel in the treatment of rosacea
- The role of brimonidine tartrate gel in the treatment of rosacea
- The role of brimonidine tartrate gel in the treatment of rosacea
- The role of brimonidine tartrate gel in the treatment of rosacea
- Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States
- Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States
- Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States
- Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States
- Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States
- Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States
- Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States
- Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial
Similar Researchers
Based on overlapping research topics